Essen BioScience & Sartorius is a team of engineers and biologists with deep expertise in cell-based assays and biomolecular interaction analysis. They invent, manufacture, supply and support instrumentation, reagents and protocols.
Accelerate to discover
Related topics
Advances in Leukemia research using shear flow and Bioflux system
Feb 3, 2023
Leukemia is a rare cancer with many subtypes. The production of abnormal leukocytes create disruptions in the immune...
Webinar: Dose Reduction and Image Enhancement in Preclinical Mouse Imaging using Deep Learning
Jan 31, 2023
In this webinar, ir. Florence Muller (Ghent University - University of Pennsylvania) is presenting two recent studies...
ACCELA Educational webinar series: Unlocking Spatial Biology with RareCyte Orion Technology
Nov 16, 2022
Discover full slide, high-plex biomarker quantitation with the all-in-one spatial biology...
Practical aspects of an imaging study: live in vivo scanning
Nov 11, 2022
In this webinar, MOLECUBES will present a live in vivo demonstration, showing the entire workflow from animal...
Advances in Leukemia research using shear flow and Bioflux system
May 24, 2022
Leukemia is a rare cancer with many subtypes. The production of abnormal leukocytes create disruptions in the immune...
In-vivo webinar: a versatile use of SPECT/CT in the development of theranostic tracers
Mar 9, 2022
Combining (preclinical) imaging and targeted therapy, is the basis of theranostics. In this webinar, Dr. Florea will...
Nov 30, 2021
Microfluidics have revolutionized...
Nov 10, 2021
Join our webinar to learn how...
Aug 21, 2017
September 7, 2017, 7 pm CEST
Chia-Wei Li, PhD, The University of Texas M. D. Anderson Cancer Center
Here we reveal PD-L1’s immunosuppression activity is stringently modulated by the spatial restraints between ubiquitination and N-linked glycosylation. We identified GSK3beta as a novel PD-L1 interacting protein capable of inducing phosphorylation dependent proteasome degradation. The essence of PD-L1 N192, N200 and N219 glycosylation suggests it antagonizes GSK3beta binding. In this regard, only non-glycosylated PD-L1 forms a complex with GSK3beta and beta-TrCP. More importantly, activation of GSK3beta-mediated PD-L1 degradation by TKI can reduce membrane PD-L1 expression and thereby enhance anti-tumor immunity. To test T cell-mediated cancer cell killing in vitro, we employed a time lapse microscopy, IncuCyte, to monitor RFP-tagged BT549 cells and activated PBMC interaction over a five day period. Massive cancer cell death was observed in glycosylation deficient cancer cells, suggesting glycosylation of PD-L1 is required for its immunosuppression. Together, our results link ubiquitination and glycosylation pathways with stringent regulation of PD-L1, proposing a new therapeutic strategy to enhance cancer immune therapy efficacy.
Learning objectives:
Related technologies: Live cell imaging | Automated microscopy and image analysis | Real-time, label free cell analysis | Cell interaction studies
Get more info
Brand profile
Essen BioScience & Sartorius is a team of engineers and biologists with deep expertise in cell-based assays and biomolecular interaction analysis. They invent, manufacture, supply and support instrumentation, reagents and protocols.
More info at:
essenbioscience.com/en/